KR20220132667A - N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민 - Google Patents

N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민 Download PDF

Info

Publication number
KR20220132667A
KR20220132667A KR1020227032393A KR20227032393A KR20220132667A KR 20220132667 A KR20220132667 A KR 20220132667A KR 1020227032393 A KR1020227032393 A KR 1020227032393A KR 20227032393 A KR20227032393 A KR 20227032393A KR 20220132667 A KR20220132667 A KR 20220132667A
Authority
KR
South Korea
Prior art keywords
ketamine
therapy
tms
tlves
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227032393A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 리차드 데보어 베스트
Original Assignee
스티븐 리차드 데보어 베스트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 리차드 데보어 베스트 filed Critical 스티븐 리차드 데보어 베스트
Priority to KR1020237031477A priority Critical patent/KR20230141875A/ko
Publication of KR20220132667A publication Critical patent/KR20220132667A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M19/00—Local anaesthesia; Hypothermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A61N2/008—Magnetotherapy specially adapted for a specific therapy for pain treatment or analgesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0055—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with electric or electro-magnetic fields
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/048—Anaesthetics
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/042—Force radial
    • F04C2270/0421—Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Social Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Treatment Devices (AREA)
KR1020227032393A 2012-11-25 2013-11-21 N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민 Ceased KR20220132667A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237031477A KR20230141875A (ko) 2012-11-25 2013-11-21 N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261729625P 2012-11-25 2012-11-25
US61/729,625 2012-11-25
US13/826,250 US8974365B2 (en) 2012-11-25 2013-03-14 Treatment of thalamocortical dysrhythmia
US13/826,250 2013-03-14
PCT/US2013/071275 WO2014081948A1 (en) 2012-11-25 2013-11-21 Treatment of thalamocortical dysrhythmia
KR1020207028289A KR20200117062A (ko) 2012-11-25 2013-11-21 시상피질 율동부정의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207028289A Division KR20200117062A (ko) 2012-11-25 2013-11-21 시상피질 율동부정의 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237031477A Division KR20230141875A (ko) 2012-11-25 2013-11-21 N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민

Publications (1)

Publication Number Publication Date
KR20220132667A true KR20220132667A (ko) 2022-09-30

Family

ID=50773848

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020207028289A Ceased KR20200117062A (ko) 2012-11-25 2013-11-21 시상피질 율동부정의 치료
KR1020227032393A Ceased KR20220132667A (ko) 2012-11-25 2013-11-21 N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민
KR1020257009861A Pending KR20250046361A (ko) 2012-11-25 2013-11-21 N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민
KR1020157015152A Ceased KR20150091323A (ko) 2012-11-25 2013-11-21 시상피질 율동부정의 치료
KR1020237031477A Ceased KR20230141875A (ko) 2012-11-25 2013-11-21 N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207028289A Ceased KR20200117062A (ko) 2012-11-25 2013-11-21 시상피질 율동부정의 치료

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020257009861A Pending KR20250046361A (ko) 2012-11-25 2013-11-21 N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민
KR1020157015152A Ceased KR20150091323A (ko) 2012-11-25 2013-11-21 시상피질 율동부정의 치료
KR1020237031477A Ceased KR20230141875A (ko) 2012-11-25 2013-11-21 N-메틸 d-아스파르트산염 수용체 (NMDAR) 길항제로서의 케타민

Country Status (10)

Country Link
US (5) US8974365B2 (enExample)
EP (2) EP2922591B1 (enExample)
JP (5) JP2016501865A (enExample)
KR (5) KR20200117062A (enExample)
CN (1) CN104981265A (enExample)
CA (1) CA2896568C (enExample)
ES (1) ES2882619T3 (enExample)
IL (2) IL273912B2 (enExample)
MX (1) MX2015006444A (enExample)
WO (1) WO2014081948A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155114B2 (en) * 2014-06-03 2018-12-18 Dirk De Ridder Systems and methods of treating a neurological disorder in a patient
US10118038B2 (en) * 2015-03-24 2018-11-06 Dirk De Ridder Methods of neuromodulation
US10201708B2 (en) 2014-10-29 2019-02-12 Dirk De Ridder Method of treating a neurological disorder using network stimulation
EP3416723A4 (en) * 2016-02-21 2019-07-17 Tech Innosphere Engineering Ltd. NONINVASIVE ELECTRICAL BRAIN STIMULATION SYSTEM
US10596378B2 (en) * 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US9950189B1 (en) * 2016-10-20 2018-04-24 Neuro-Laser Foundation Inc. Treatment methodologies using light therapy
US10905897B2 (en) * 2016-10-20 2021-02-02 Neuro-Laser Foundation, Inc. Synergistic treatment methodologies using light therapy
WO2019060298A1 (en) 2017-09-19 2019-03-28 Neuroenhancement Lab, LLC METHOD AND APPARATUS FOR NEURO-ACTIVATION
CA3076180C (en) * 2017-11-22 2022-05-17 Excelsior Pharmatech Labs Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
KR102099200B1 (ko) * 2017-12-18 2020-04-09 서울대학교산학협력단 뇌 자극 장치
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
CN113382683A (zh) 2018-09-14 2021-09-10 纽罗因恒思蒙特实验有限责任公司 改善睡眠的系统和方法
CN109481845B (zh) * 2018-12-28 2022-04-01 深圳先进技术研究院 一种作用于不同脑区的经颅磁刺激的方法和相关装置
CN110064117B (zh) * 2019-03-27 2021-06-01 佛山职业技术学院 一种基于呐喊声音的心理宣泄交互方法及装置
WO2020196888A1 (ja) 2019-03-28 2020-10-01 住友建機株式会社 ショベル及び施工システム
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US12059565B1 (en) * 2019-12-19 2024-08-13 Washington University Methods and systems for modulating unconsciousness or anesthesia in a subject
CN113041501A (zh) * 2021-03-22 2021-06-29 东南大学 联合磁刺激系统靶向视觉皮层快速抗抑郁的方法
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression
ES2994763B2 (es) * 2023-07-25 2025-11-03 Nauta Technomedical Res S L Sistema de neuroestimulacion magnetica hiperbarica con ajuste parametrico semi automatico personalizable

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084007A (en) * 1989-08-11 1992-01-28 Malin David H Method for chemical promotion of the effects of low current transcranial electrostimulation
US6132361A (en) * 1994-11-28 2000-10-17 Neotonus, Inc. Transcranial brain stimulation
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6591138B1 (en) * 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US20110307029A1 (en) * 2008-08-06 2011-12-15 Cerephex Corporation Brain stimulation methods for treating central sensitivity
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US8052591B2 (en) * 2006-05-05 2011-11-08 The Board Of Trustees Of The Leland Stanford Junior University Trajectory-based deep-brain stereotactic transcranial magnetic stimulation
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7603174B2 (en) * 2004-10-21 2009-10-13 Advanced Neuromodulation Systems, Inc. Stimulation of the amygdalohippocampal complex to treat neurological conditions
CN101686945A (zh) * 2004-11-23 2010-03-31 埃德莫斯药品有限公司 包含持续释放的包衣或基质和nmda受体拮抗剂的组合物，以及向受治疗者施用该nmda受体拮抗剂的方法
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8676330B2 (en) * 2009-03-20 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
WO2007103475A2 (en) * 2006-03-07 2007-09-13 Beth Israel Deaconess Medical Center, Inc. Transcranial magnetic stimulation (tms) methods and apparatus
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
US7949403B2 (en) * 2007-02-27 2011-05-24 Accelerated Care Plus Corp. Electrical stimulation device and method for the treatment of neurological disorders
WO2009137843A2 (en) * 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
JP5597198B2 (ja) * 2008-07-14 2014-10-01 アリゾナ・ボード・オブ・リージェンツ・フォー・アンド・オン・ビハーフ・オブ・アリゾナ・ステイト・ユニバーシティ 超音波を使用して細胞活動を調節するための方法およびデバイス
US8801589B2 (en) * 2008-08-04 2014-08-12 The Trustees Of Columbia University In The City Of New York Methods, apparatus, and systems for magnetic stimulation
WO2010071846A2 (en) 2008-12-19 2010-06-24 Afraxis, Inc. Compounds for treating neuropsychiatric conditions
JP5688380B2 (ja) 2009-03-02 2015-03-25 エダ リサーチ アンド ディベロップメント カンパニー，リミティド 経頭蓋磁気刺激用の磁気構造とタイミング方式
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
JP2013507395A (ja) * 2009-10-09 2013-03-04 アフラクシス・インコーポレイテッド Ｃｎｓ障害治療用の８−エチル−６−（アリール）ピリド［２，３−ｄ］ピリミジン−７（８ｈ）−オン
CA2784119A1 (en) 2009-12-15 2011-06-23 Neurop, Inc. Compounds for the treatment of neurologic disorders
US20130096363A1 (en) * 2010-04-02 2013-04-18 M. Bret Schneider Neuromodulation of deep-brain targets by transcranial magnetic stimulation enhanced by transcranial direct current stimulation
US20140058189A1 (en) * 2012-02-20 2014-02-27 William F. Stubbeman Systems and methods using brain stimulation for treating disorders

Also Published As

Publication number Publication date
CA2896568A1 (en) 2014-05-30
US20180001104A1 (en) 2018-01-04
CA2896568C (en) 2025-06-17
KR20150091323A (ko) 2015-08-10
US20150165224A1 (en) 2015-06-18
US20210101015A1 (en) 2021-04-08
KR20230141875A (ko) 2023-10-10
US8974365B2 (en) 2015-03-10
IL238979B (en) 2020-08-31
JP2022188221A (ja) 2022-12-20
JP2016501865A (ja) 2016-01-21
CN104981265A (zh) 2015-10-14
JP2020180141A (ja) 2020-11-05
US10716950B2 (en) 2020-07-21
KR20250046361A (ko) 2025-04-02
EP2922591B1 (en) 2021-05-12
EP3915551A1 (en) 2021-12-01
US20240207630A1 (en) 2024-06-27
KR20200117062A (ko) 2020-10-13
EP2922591A1 (en) 2015-09-30
IL273912B2 (en) 2024-11-01
HK1215687A1 (zh) 2016-09-09
WO2014081948A1 (en) 2014-05-30
IL273912A (en) 2020-05-31
EP2922591A4 (en) 2016-08-10
ES2882619T3 (es) 2021-12-02
IL273912B1 (en) 2024-07-01
MX2015006444A (es) 2015-10-29
IL238979A0 (en) 2015-07-30
US9649501B2 (en) 2017-05-16
US20140148636A1 (en) 2014-05-29
JP2025029043A (ja) 2025-03-05
JP2019065021A (ja) 2019-04-25

Similar Documents

Publication Publication Date Title
JP2025029043A (ja) 視床皮質律動異常の処置
Bystritsky et al. A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder.
Sjogren et al. Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study
Karsen et al. Review of the effectiveness of transcranial magnetic stimulation for post-traumatic stress disorder
Sator-Katzenschlager et al. Electrical stimulation of auricular acupuncture points is more effective than conventional manual auricular acupuncture in chronic cervical pain: a pilot study
US10596378B2 (en) Method for treatment of depression using synaptic pathway training
Hu et al. Repetitive transcranial magnetic stimulation-induced seizure of a patient with adolescent-onset depression: a case report and literature review
US20200222656A1 (en) Method for treatment of depression using synaptic pathway training
Katsuki et al. Lance-Adams syndrome treated by perampanel in the acute term
Kirkcaldie et al. Bridging the skull: electroconvulsive therapy (ECT) and repetitive transcranial magnetic stimulation (rTMS) in psychiatry
Fotuhi et al. The effects of obesity on brain structure and size
Mindes et al. Cranial electrical stimulation
Fymat Electromagnetic Therapy for Neurological and Neurodegenerative Diseases: I Peripheral Brain Stimulations
McDonald et al. Electroconvulsive therapy: sixty years of progress and a comparison with transcranial magnetic stimulation and vagal nerve stimulation
HK1215687B (en) Treatment of thalamocortical dysrhythmia
Pietrobon et al. Audiovisual production therapy associated with transcranial direct current stimulation (tDCS) improves naming in patients with non-fluent aphasia: A randomized, double-blind, placebo-controlled study
Lloyd Investigations of mode of action of single pulse Transcranial Magnetic Stimulation (sTMS) in animal models and effectiveness in migraine patients
Baker et al. Clinical applications of electroconvulsive therapy and transcranial magnetic stimulation for the treatment of major depressive disorder: a critical review
Thomson et al. The impact of deep brain stimulation on personality, identity, and relationships in neurological and psychiatric conditions
Mindes et al. Cranial Electrical Stimulation 11
Brinkhaus Acupuncture for Chronic Heart Failure
Deckert The Effects of Transcranial Direct Current Stimulation (tDCS) on Fatigue During Maximal Intensity Exercise
Han et al. Suppression of Motor Evoked Potential and H-reflex during Cataplexy in Narcolepsy
Chen et al. Research Article Electroacupuncture Reduces Cocaine-Induced Seizures and Mortality in Mice

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220919

Application number text: 1020207028289

Filing date: 20200929

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20221018

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230316

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230921

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230316

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I